CA-NETAPP,-INC.
20.10.2021 17:02:11 CEST | Business Wire | Press release
NetApp (NASDAQ: NTAP) a global, cloud-led, data-centric software company, today announced continued growth and momentum helping organizations unlock the best of cloud at less cost, through its collaboration with the world’s three largest public clouds.
NetApp’s expansion in the cloud has been driven by customers and supported by these partnerships, accelerating NetApp’s public cloud services’ customer and financial growth by bringing its leading CloudOps and ITOps solutions to existing and new addressable customers. Furthering its investment in the cloud, NetApp acquired Data Mechanics in early fiscal year (FY)’22, and this month announced the intent to acquire CloudCheckr to bolster the Spot by NetApp portfolio’s existing continuous cloud optimization capabilities.
This growth, driven by NetApp’s ONTAP data management software, which provides high-performance shared storage for file and block workloads, has propelled the native integration of NetApp’s cloud file services into each of the major public clouds.
“The three largest public clouds in the world are choosing NetApp, because customers are choosing ONTAP,” said Anthony Lye, Executive Vice President & General Manager, Public Cloud Services at NetApp. “Our strategy has positioned ONTAP as the native shared storage solution with rich data services inside the three public clouds. Now, our public cloud partners provide customers with the simplest path to the cloud and allow them to derive the most value from their data and applications.”
“The completeness of NetApp’s offering, combined with the ability to address a very broad set of storage use cases beyond cloud file storage, and the availability as a Tier 1 offering both on AWS and Azure, makes it a compelling choice,” said Enrico Signoretti, Senior Data Storage Analyst at GigaOm.1
Microsoft Azure
NetApp has partnered with Microsoft for nearly 30 years. In 2021 Microsoft recognized NetApp as the global Customer Experience Partner of the Year , and the U.S. SAP on Azure Partner of the Year . In the last 12 months, NetApp has more than tripled the number of co-sells offered on the Azure Marketplace, making it easy for Azure customers to consume NetApp’s leading cloud services.
Since its general availability in 2019, Azure NetApp Files (ANF), a fully managed, first-party service sold, billed, and supported by Microsoft in 35+ regions globally and is the first and only shared file service certified for use with SAP HANA. Recent innovations with Azure include the general availability of Azure Cross Region Replication, public preview of Azure NetApp Files Backup to preserve storage efficiencies, and of Spot PC for secure, optimized Azure Virtual Desktop-based Cloud PC environments.
“Alongside NetApp, we have worked with ANF customers to successfully migrate and run some of their largest and most important ONTAP production workloads, enabling the most demanding applications with performance and scale that meets or beats what they get on-premises,” said Jurgen Willis, Vice President, Product Management at Microsoft Azure Storage.
“With ANF, we get scalability and flexibility, which is important for businesses to run and have a faster time-to-market for their products,” said Lalit Patel, Chief Technology Officer, Enterprise Cloud Services at SAP. “We are able to deploy environments almost 30 to 40 percent faster and reduce the number of outages by 80 percent because of the stability that ANF provides.”
Google Cloud
NetApp and Google Cloud began collaborating in 2018, introduced NetApp Cloud Volumes Service (CVS) for Google Cloud in 2019, and launched NetApp Astra with support for Google Cloud in 2020. Earlier this month Google announced that NetApp would serve as the primary data and storage vendor for its new Google Distributed Cloud Hosted offering and introduced the integration of Google Cloud VMware Engine with NetApp Cloud Volumes Service support for VM datastores - a fully managed service that helps organizations meet their need for virtual workload storage and disaster recovery.
“Our partnership with NetApp continues to grow, rolling out new capabilities that will make it easier and more cost-effective to deliver enterprise workloads on Google Cloud and bringing customers even more flexibility across hybrid and cloud deployments,” said Bronwyn Hastings, Vice President Global Technology Partnerships at Google Cloud.
“With NetApp's deep integrations with Google Cloud, we're reaping all of the benefits of the cloud as a service, with configurations preset, elasticity built-in and disaster recovery capabilities in place within five minutes,” said Tom Gentry, Technologist at Gunpowder. “By making the technology challenges disappear for these studios, we're able to deliver the high performance our customers need anywhere in the world.”
Additionally, Spot by NetApp and Google Cloud have partnered to help companies take full advantage of the recently announced Google Spot VMs . With this, Google Cloud customers can continuously optimize performance, availability and cost with Spot by NetApp for cloud cost savings without the risk of service interruption.
Additional Resources
- Press Release: NetApp Expands Hybrid Cloud Solutions Portfolio to Unlock Best of Cloud at INSIGHT 2021 Digital
- Blog post: Ungated Innovation: Azure NetApp Files
- Blog post: NetApp INSIGHT ‘21 - Google Cloud Momentum
About NetApp
NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
1 Source: GigaOm, Radar for Cloud File Systems, September 22, 2021
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005583/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom